Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome
- Park, Sungwoo; Baek, Dong Won; Sohn, Sang Kyun; Ahn, Jae-Sook; Kim, Hyeoung-Joon; Shin, Ho Fin; Chung, Joo Seop; Lee, Sang Min; Lee, Won Sik; Lim, Sung Nam; Lee, Yoo Fin; Choi, Yunsuk; Lee, Ho Sup; Cho, Yoon Young; Lee, Gyeong-Won; Moon, Joon Ho
- Issue Date
- CIG MEDIA GROUP, LP
- Allogeneic hematopoietic cell transplantation; BM blast; Hypomethylating agents; IPSS; Myelodysplastic syndrome
- CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, v.19, no.7, pp.E367 - E373
- Journal Title
- CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
- Start Page
- End Page
- To evaluate the clinical significance of tumor burden reduction for transplant-eligible patients with higher risk myelodysplastic syndrome, data of 79 patients were retrospectively analyzed. A follow-up higher risk International Prognostic Scoring System was correlated with overall survival. The optimal time for tumor burden evaluation is prior to follow-up rather than at the time of initial diagnosis. Introduction: The clinical significance of tumor burden reduction following administration of hypomethylating agents (HMAs) for transplant-eligible patients with higher risk myelodysplastic syndrome (MDS) was evaluated. Patients and Methods: Data of 79 transplant-eligible patients (< 65 years) diagnosed with higher-risk MDS between July 2002 and March 2013 were retrospectively analyzed. Among 79 patients, 30 (38%) underwent allogeneic hematopoietic cell transplantation (HCT group), and 49 (62%) were treated with HMA alone (non-HCT group). Results: The median follow-up duration was 732 days (range, 28-1952 days), and the 3-year overall survival (OS) rate of all patients was 30.6%. In the HCT group, early HCT showed a better 3-year OS rate than late HCT (67.1% vs. 25.7%; P = .035). In multivariate analysis, time/performance of allogenic transplant (no HCT vs. early HCT, hazard ratio, 0.18; 95% confidence interval, 0.04-0.81; P = .026) and follow-up higher risk International Prognostic Scoring System (hazard ratio, 6.22; 95% confidence interval, 2.09-18.51; P = .001) were significantly correlated with OS. Conclusion: To predict the clinical outcomes of patients with higher risk MDS, the optimal time for tumor burden evaluation is prior to follow-up rather than at the time of initial diagnosis. Patients with lower International Prognostic Scoring System risk groups after HMA treatment or early HCT had favorable OS.
- Files in This Item
- There are no files associated with this item.
- Appears in
- College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.